AFT Pharmaceuticals — Making progress on growth strategy
AFT Pharmaceuticals has provided an investor update for Q2 CY25 (Q1 FY26), summarising material progress made across its global expansion and...
189 Views
AFT Pharmaceuticals — Setting the stage for sustained long-term growth
AFT Pharmaceuticals reported FY25 revenues of N Z$208m, posting a strong recovery in H2, with dissipating headwinds and traditional H2 seasonality...
271 Views
AFT Pharmaceuticals - Softer H1 on one-offs; recovery expected in H2
AFT Pharmaceuticals reported H125 revenues of NZ$86.7m, a 3.7% y-o-y increase, albeit lower than expected due to one-off factors such as inventory...
402 Views
AFT Pharmaceuticals - H125 profitability weighed down by one-offs
AFT Pharmaceuticals has released a trading update ahead of its H125 results, expecting to report a c NZ$2m operating loss for the period ending...
246 Views
AFT Pharmaceuticals - Maxigesic IV reaches the Chinese shores
AFT Pharmaceuticals has taken another major step in extending its international footprint, with the signing of an exclusive license agreement for...
352 Views